 | Up a level |
Journal Article
Borchmann, S., Goergen, H., Sasse, S., Kreissl, S., Broeckelmann, P. J., von Tresckow, B., Fuchs, M., Diehl, V. and Engert, A. (2018). Pretreatment vitamin D deficiency is associated with lower progression free and overall survival in prospectively treated Hodgkin lymphoma. Oncol. Res. Treat., 41. S. 273 - 275. BASEL: KARGER. ISSN 2296-5262
Borchmann, S., Hude, I., Sasse, S., Broeckelmann, P., von Tresckow, B., Momotow, J. and Engert, A. (2017). Leukocyte and eosinophil count at baseline predict outcome in relapsed or refractory classical Hodgkin lymphoma patients treated with immune checkpoint inhibitors. Oncol. Res. Treat., 40. S. 142 - 144. BASEL: KARGER. ISSN 2296-5262
Eich, H. T., Kriz, J., Klimm, B., Sasse, S., Goergen, H., Diehl, V., Borchmann, P., Mueller, R. and Engert, A. (2012). Involved-field (IF) Versus Extended-field (EF) Radiation Therapy (RT) for Patients in Early Unfavorable Stages of Hodgkin Lymphoma: 10-year Update of the HD8 Trial of the German Hodgkin Study Group (GHSG). Int. J. Radiat. Oncol. Biol. Phys., 84 (3). S. S70 - 1. NEW YORK: ELSEVIER SCIENCE INC. ISSN 0360-3016
Fritsch, K., Kasenda, B., Schorb, E., Hau, P., Bloehdorn, J., Moehle, R., Loew, S., Binder, M., Atta, J., Keller, U., Wolf, H-H, Krause, S. W., Hess, G., Naumann, R., Sasse, S., Hirt, C., Lamprecht, M., Martens, U., Morgner, A., Panse, J., Frickhofen, N., Roeth, A., Hader, C., Deckert, M., Fricker, H., Ihorst, G., Finke, J. and Illerhaus, G. (2017). High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). Leukemia, 31 (4). S. 846 - 853. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Fuchs, M., Wongso, D., Pluetschow, A., Feuring-Buske, M., Hertenstein, B., Hoeffkes, H. -G, Vogelhuber, M., von Tresckow, B., Biersack, H., Link, H., Topp, M. S., Fischer, N., Bredenfeld, H., Sasse, S., Behringer, K., Boell, B., Borchmann, P. and Engert, A. (2014). Final analysis of a randomized phase II trial with prednisone, vinblastine, doxorubicin, and gemcitabine in patients with early unfavorable Hodgkin lymphoma -PVAG-14 pilot-. Oncol. Res. Treat., 37. S. 11 - 12. BASEL: KARGER. ISSN 2296-5262
Fuchs, M., Wongso, D., Pluetschow, A., Feuring-Buske, M., Hertenstein, B., Hoeffkes, H. G., Vogelhuber, M., von Tresckow, B., Biersack, H., Link, H., Topp, M. S., Fischer, N., Bredenfeld, H., Sasse, S., Behringer, K., Boell, B., Borchmann, P. and Engert, A. (2014). FINAL ANALYSIS OF A RANDOMIZED PHASE II STUDY WITH PREDNISONE, VINBLASTINE, DOXORUBICIN, AND GEMCITABINE IN PATIENTS WITH EARLY UNFAVORABLE HODGKIN LYMPHOMA -PVAG-14 PILOT-. Haematologica, 99. S. 497 - 498. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Hude, I., Sasse, S., Broeckelmann, P. J., von Tresckow, B., Momotow, J., Engert, A. and Borchmann, S. (2017). BASELINE LEUKOCYTE AND EOSINOPHIL COUNTS PREDICT OUTCOME IN RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA PATIENTS TREATED WITH PD1 INHIBITION. Haematologica, 102. S. 460 - 461. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Jakob, T., Follmann, M., Borchmann, P., Baues, C., Sasse, S., Broeckelmann, P. J., Kreissl, S., Eichenauer, D., von Tresckow, B., Buerkle, C., Engert, A. and Skoetz, N. (2018). Guideline update on diagnosis, therapy and follow-up of adult Hodgkin lymphoma patients. Oncol. Res. Treat., 41. S. 17 - 18. BASEL: KARGER. ISSN 2296-5262
Momotow, J., Sasse, S., Pluetschow, A., Huettmann, A., Basara, N., Koenecke, C., Martin, S., Bentz, M., Grosse-Thie, C., Thorspecken, S., de Wit, M., Kobe, C., Dietlein, M., von Tresckow, B., Fuchs, M., Borchmann, P. and Engert, A. (2020). AFM13 in patients with relapsed or refractory Hodgkin Lymphoma: Final results of an open-label, randomized, multicenter phase II trial. Oncol. Res. Treat., 43 (SUPPL 4). S. 89 - 90. BASEL: KARGER. ISSN 2296-5262
Sasse, S., Behringer, K., Semrau, R. and Engert, A. (2014). Controversies in the treatment of early and intermediate stage Hodgkin's lymphoma. Onkologe, 20 (5). S. 448 - 455. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0415
Sasse, S., Broeckelmann, P. J., Baues, C., Eich, H. T. and Engert, A. (2018). Treatment of early stage Hodgkin lymphoma. Discussion of current trials and treatment recommendations. Onkologe, 24 (4). S. 303 - 315. NEW YORK: SPRINGER. ISSN 1433-0415
Sasse, S., Broeckelmann, P. J., Goergen, H., Pluetschow, A., Mueller, H., Kreissl, S., Buerkle, C., Borchmann, S., Fuchs, M., Borchmann, P. and Engert, A. (2016). LONG-TERM FOLLOW-UP OF CONTEMPORARY TREATMENT IN EARLY-STAGE FAVORABLE HODGKIN LYMPHOMA: UPDATED ANALYSES OF THE GERMAN HODGKIN STUDY GROUP HD7 AND HD10 TRIAL. Haematologica, 101. S. 12 - 13. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Sasse, S., Broeckelmann, P. J., Goergen, H., Pluetschow, A., Mueller, H., Kreissl, S., Buerkle, C., Borchmann, S., Fuchs, M., Borchmann, P. and Engert, A. (2016). LONG-TERM FOLLOW-UP OF CONTEMPORARY TREATMENT IN EARLY-STAGE UNFAVORABLE HODGKIN LYMPHOMA: UPDATED ANALYSES OF THE GERMAN HODGKIN STUDY GROUP HD8 AND HD11 TRIAL. Haematologica, 101. S. 13 - 15. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Sasse, S., Klimm, B., Goergen, H., Fuchs, M., Heyden-Honerkamp, A., Lohri, A., Koch, O., Wilhelm, M., Trenn, G., Finke, J., Mueller, R. P., Diehl, V., Eich, H. T., Borchmann, P. and Engert, A. (2012). Comparing long-term toxicity and efficacy of combined modality treatment including extended- or involved-field radiotherapy in early-stage Hodgkin's lymphoma. Ann. Oncol., 23 (11). S. 2953 - 2960. OXFORD: OXFORD UNIV PRESS. ISSN 0923-7534
Sasse, S., Momotow, J., Broeckelmann, P. J., Baues, C., Eich, H. T. and Engert, A. (2022). Treatment of early stage favorable and unfavorable Hodgkin lymphoma. Onkologie, 28 (10). S. 879 - 889. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 2731-7234
Sasse, S., Momotow, J. and Engert, A. (2020). Checkpoint inhibitors in Hodgkin lymphoma. Internist, 61 (7). S. 660 - 669. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-1289
Zinzani, P. L., Sasse, S., Radford, J., Gautam, A. and Bonthapally, V. (2016). Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma: An updated review of published data from the named patient program. Crit. Rev. Oncol./Hematol., 104. S. 65 - 71. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1879-0461
Zinzani, P. L., Sasse, S., Radford, J., Shonukan, O. and Bonthapally, V. (2015). Experience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: Review of the literature. Crit. Rev. Oncol./Hematol., 95 (3). S. 359 - 370. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1879-0461
von Tresckow, B., Goebeler, M. E., Sayehli, C., Gundermann, S., Eichenauer, D., Aulitzky, W., Bacchus, L., Igel, S., Schwab, M., Sasse, S., Hauns, B., Mais, A., Hentsch, B., Kohlhof, H., Krauss, R., Krauss, B., Baumgartner, R., Vitt, D. and Engert, A. (2014). FIRST-IN-MAN STUDY OF 4SC-202, A NOVEL ORAL HDAC INHIBITOR IN PATIENTS WITH ADVANCED HEMATOLOGICAL MALIGNANCIES; (TOPAS STUDY). Haematologica, 99. S. 711 - 712. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
von Tresckow, B., Kreissl, S., Haverkamp, H., Sasse, S., Diehl, V., Engert, A. and Borchmann, P. (2016). BEACOPP-ESCALATED FOLLOWED BY RADIOTHERAPY OF INITIAL BULK OR RESIDUAL DISEASE IN ADVANCED-STAGE HODGKIN LYMPHOMA: LONG-TERM FOLLOW-UP OF THE GHSG HD9 AND HD12 TRIALS. Haematologica, 101. S. 18 - 19. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078